Hyperthermic Intraperitoneal Chemotherapy With Chenotherapy In Ovarian Cancer:A Meta-analysis

Objective:To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy used with intravenous chemotherapy in ovarian cancer.Method:We searched PuMbed,Cochrane Library,Clinicaltrail.gov,CNKI,Embase and the Chinese biomedical database(CBM)for all randomized controlled trails about HIPEC used with intravenous chemotherapy versus intravenous chemotherapy.The last search by January 2019.Screened studies independently by 2 researchers according to inclusion and exclusion criteria.The risk of bias of the included studies was evaluated via Cochrane systematic evaluation.Revman5.3 was used for statistical analysis.Results:Totally 14 randomized controlled studies including 1373 patients,while 685 in the experimental group and 688 in the control group.The results showed that HIPEC used with intravenous chemotherapy group was superior to the intravenous chemotherapy in 3-year survival rates[RR = 1.44,95% CI(1.31-1.59)],the 5-year survival rates [ RR = 1.40,95% CI(1.15-1.70)]and clinical efficient[OR=3.15,95%CI(2.11-4.69)].In terms of the safety,two groups has no statistical significance.Conclusion:Compared with intravenous chemotherapy,hyperthermic intraperitoneal chemotherapy used with intravenous chemotherapy has advantege in the short-term efficacy and long-term survival.Addtionally,it is safe and feasible,so it is recommended to clinical.